Clinical Trial

NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Cognitive impairment, the core psychopathology of schizophrenia, usually persists in schizophrenia patients even during symptomatic remission. While cognitive impairment associated with schizophrenia (CIAS) is an important therapeutic target, hypofunction of N-methyl-D-aspartate receptor (NMDAR) is a key factor of CIAS. This study aims to examine the efficacy and safety of an NMDA-enhancer (NMDAE) for the treatment of CIAS in schizophrenia patients during symptomatic remission.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-08-31; most recent amendment 2025-02-16.
Status change: Not Yet Recruiting → Recruiting 2023-10-18
Trial Details
NCT Number NCT06021197
Lead Sponsor China Medical University Hospital
Collaborators: National Science and Technology Council, Taiwan
Conditions Schizophrenia
Enrollment 90 participants
Start Date 2023-10-12
Primary Completion 2027-12 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2025-02-19